Advertisement
Table 2 Summary of adverse drug reactions
| e | n (%) | |
|---|---|---|
| IMP-related adverse events | 95 | 34 (36.6) |
| Severity | ||
| Mild | 95 | 34 (36.6) |
| Moderate | 0 | 0 |
| Severe | 0 | 0 |
| Change in treatment schedule | ||
| None | 93 | 33 (35.5) |
| Temporarily interrupted | 2 | 1 (1.1) |
| Discontinued | 0 | 0 |
| Prior to first intake | 0 | 0 |
| Classification according to EAACI guideline | ||
| LR | 85 | 32 (34.4) |
| SR | 9 | 4 (4.3) |
| Grade 0/Nonspecific | 1 | 1 (1.1) |
| Dose | ||
| 300 SQ+ | 16 | 13 (14.0) |
| 600 SQ+ | 11 | 11 (11.8) |
| 3,000 SQ+ | 24 | 22 (23.7) |
| 6,000 SQ+ | 17 | 17 (18.3) |
| 15,000 SQ+ | 26 | 15 (16.1) |
| Dose unknown | 1 | 1 (1.1) |
